KLHL3 Activators are a diverse set of chemical compounds that enhance the protein's regulatory functions in electrolyte balance and blood pressure homeostasis. Sodium Chloride, in hypertonic doses, and Lithium can perturb the WNK-SPAK/OSR1 pathway, which is crucial for ion transport in the kidney, thereby indirectly necessitating increased KLHL3-mediated ubiquitination to restore homeostasis. Aldosterone antagonists like EKLHL3 Activators are a diverse set of chemical compounds that enhance the protein's regulatory functions in electrolyte balance and blood pressure homeostasis. Sodium Chloride, in hypertonic doses, and Lithium can perturb the WNK-SPAK/OSR1 pathway, which is crucial for ion transport in the kidney, thereby indirectly necessitating increased KLHL3-mediated ubiquitination to restore homeostasis. Aldosterone antagonists like Eplerenone, along with diuretics such as Hydrochlorothiazide and Chlorthalidone, challenge the salt-retaining mechanisms, thereby enhancing the role of KLHL3 in modulating the degradation of the Na-Cl cotransporter (NCC) to maintain blood pressure and electrolyte balance. Moreover, the engagement of RAAS components by Angiotensin II, and its receptor blockers such as Losartan, Candesartan, and Valsartan, indirectly calls upon KLHL3's activity to counterbalance the shifts in homeostatic control exerted by this system.
The functional enhancement of KLHL3 is also influenced by compounds that affect sodium reabsorption channels. Amiloride and Triamterene, by inhibiting epithelial sodium channels (ENaC), indirectly promote KLHL3 activity to adjust the homeostatic balance. This compensatory effect ensures that KLHL3 activity is upregulated to maintain sodium equilibrium when ENaC is inhibited. The collective actions of these chemicals not only underscore the vital role of KLHL3 in kidney function and systemic blood pressure regulation but also highlight the intricacies of ion transport modulation. Through their targeted effects on various signaling pathways and ion transport mechanisms, these activators enhance the function of KLHL3, thereby facilitating the maintenance of electrolyte balance and vascular tone without altering the protein's expression levels or direct activation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Angiotensin II, Human | 4474-91-3 | sc-363643 sc-363643A sc-363643B sc-363643C | 1 mg 5 mg 25 mg 100 mg | $50.00 $75.00 $260.00 $505.00 | 3 | |
Angiotensin II interacts with its receptor to potentiate the activity of the WNK-SPAK/OSR1 pathway. As KLHL3 targets WNK for degradation, the presence of Angiotensin II might enhance KLHL3's activity to maintain homeostasis by regulating this pathway and preventing overactivation. | ||||||
Aldosterone | 52-39-1 | sc-210774 sc-210774A sc-210774B sc-210774C sc-210774D sc-210774E | 2 mg 5 mg 10 mg 50 mg 100 mg 250 mg | $254.00 $209.00 $311.00 $1520.00 $3014.00 $7487.00 | 1 | |
Aldosterone is involved in the regulation of sodium and potassium balance. Its action may increase the functional demand on KLHL3 for the degradation of WNK kinases, indirectly enhancing KLHL3's activity to maintain electrolyte balance. | ||||||
Amiloride | 2609-46-3 | sc-337527 | 1 g | $290.00 | 7 | |
Amiloride inhibits sodium channels in the distal nephron. This can indirectly upregulate KLHL3 activity as the body tries to counteract the effects of the drug by modulating the WNK-SPAK/OSR1 signaling pathway. | ||||||
Hydrochlorothiazide | 58-93-5 | sc-207738 sc-207738A sc-207738B sc-207738C sc-207738D | 5 g 25 g 50 g 100 g 250 g | $54.00 $235.00 $326.00 $551.00 $969.00 | ||
Hydrochlorothiazide is a diuretic that could indirectly enhance KLHL3 activity by causing alterations in electrolyte reabsorption that would require KLHL3-mediated regulation of WNK kinase levels. | ||||||
Eplerenone | 107724-20-9 | sc-203943 sc-203943A | 10 mg 50 mg | $108.00 $612.00 | 4 | |
Eplerenone, a selective aldosterone blocker, may indirectly enhance KLHL3 activity by affecting the WNK-SPAK/OSR1 pathway, which KLHL3 is known to regulate. | ||||||
Ouabain-d3 (Major) | sc-478417 | 1 mg | $506.00 | |||
Ouabain is a Na+/K+-ATPase inhibitor, which could lead to compensatory mechanisms that enhance KLHL3 activity to regulate ion homeostasis. | ||||||
Captopril | 62571-86-2 | sc-200566 sc-200566A | 1 g 5 g | $48.00 $89.00 | 21 | |
Captopril, an ACE inhibitor, could indirectly enhance KLHL3 activity by modulating the renin-angiotensin-aldosterone system, affecting the electrolyte balance and thus KLHL3's role in it. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $127.00 | 18 | |
Losartan, an angiotensin II receptor antagonist, might enhance KLHL3 activity indirectly by modulating the downstream effects on the WNK-SPAK/OSR1 pathway. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $58.00 $170.00 | 15 | |
Nifedipine, a calcium channel blocker, could indirectly enhance KLHL3 activity by affecting calcium signaling pathways that intersect with KLHL3's regulatory functions. | ||||||
Metolazone | 17560-51-9 | sc-211900 | 100 mg | $224.00 | ||
Metolazone, a diuretic affecting electrolyte reabsorption, could enhance KLHL3's ubiquitin ligase activity indirectly by altering the functional load on the WNK-SPAK/OSR1 pathway. |